Denali Therapeutics’ (DNLI) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Denali Therapeutics (NASDAQ:DNLI) in a research report released on Thursday morning, Benzinga reports. The brokerage currently has a $90.00 price target on the stock.

Other equities analysts have also issued reports about the stock. JPMorgan Chase & Co. increased their price target on shares of Denali Therapeutics from $28.00 to $29.00 and gave the company an overweight rating in a research note on Wednesday, July 10th. Citigroup increased their target price on shares of Denali Therapeutics from $26.00 to $32.00 and gave the company a buy rating in a research report on Friday, August 2nd. Stifel Nicolaus reduced their price target on shares of Denali Therapeutics from $26.00 to $22.00 and set a hold rating for the company in a research report on Wednesday, May 8th. Finally, Wedbush dropped their price objective on Denali Therapeutics from $30.00 to $26.00 and set an outperform rating on the stock in a report on Friday, August 2nd. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of Moderate Buy and a consensus target price of $39.33.

Denali Therapeutics Trading Down 2.7 %

Shares of DNLI stock opened at $23.02 on Thursday. Denali Therapeutics has a 12 month low of $14.56 and a 12 month high of $25.24. The company has a market cap of $3.28 billion, a P/E ratio of -23.98 and a beta of 1.40. The firm has a fifty day moving average price of $22.38 and a 200 day moving average price of $20.00.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Thursday, August 1st. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.09. The business had revenue of $1.00 million for the quarter, compared to analyst estimates of $10.00 million. During the same period in the prior year, the company posted $1.30 earnings per share. The company’s revenue was down 99.7% compared to the same quarter last year. On average, equities analysts forecast that Denali Therapeutics will post -2.77 EPS for the current year.

Insider Activity

In related news, Director Jennifer E. Cook sold 1,458 shares of the firm’s stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $21.73, for a total transaction of $31,682.34. Following the transaction, the director now owns 20,038 shares of the company’s stock, valued at $435,425.74. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, Director Jennifer E. Cook sold 1,458 shares of Denali Therapeutics stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $21.73, for a total value of $31,682.34. Following the transaction, the director now directly owns 20,038 shares in the company, valued at approximately $435,425.74. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Steve E. Krognes sold 30,000 shares of the company’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $22.12, for a total transaction of $663,600.00. Following the transaction, the director now owns 34,404 shares of the company’s stock, valued at approximately $761,016.48. The disclosure for this sale can be found here. Over the last three months, insiders sold 32,146 shares of company stock valued at $710,274. Insiders own 7.90% of the company’s stock.

Institutional Investors Weigh In On Denali Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. EP Wealth Advisors LLC acquired a new stake in shares of Denali Therapeutics in the 1st quarter valued at approximately $831,000. Edmond DE Rothschild Holding S.A. boosted its position in shares of Denali Therapeutics by 65.9% during the 4th quarter. Edmond DE Rothschild Holding S.A. now owns 165,680 shares of the company’s stock worth $3,555,000 after purchasing an additional 65,800 shares in the last quarter. Pathway Capital Management LP acquired a new position in shares of Denali Therapeutics during the 4th quarter worth $1,490,000. Edgestream Partners L.P. purchased a new position in shares of Denali Therapeutics in the 1st quarter valued at about $2,301,000. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in shares of Denali Therapeutics in the first quarter valued at about $4,330,000. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.